Ethanol extract of cirsium japonicum attenuates hepatic lipid accumulation via AMPK activation in human HepG2 cells

Experimental and Therapeutic Medicine

Volumn 8, Issue 1, 2014, Pages 79-84

  Wan, Yun ^a   Liu, Li Ya ^a   Hong, Zhen Feng ^a   Peng, Jun ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

AMP activated protein kinase; Cirsium japonicum; Fatty acid oxidation; Nonalcoholic fatty liver disease

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BETA ACTIN; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; CIRSIUM JAPONICUM EXTRACT; COMPLEMENTARY DNA; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CELL VIABILITY ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACTION AND EXTRACTS; FATTY ACID OXIDATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID STORAGE; LIVER PROTECTION; MTT ASSAY; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; RADIOIMMUNOPRECIPITATION; RNA EXTRACTION; WESTERN BLOTTING;

EID: 84901363757     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1698     Document Type: Article

References (22)

1. Koo SH: Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19: 210-215, 2013.
2. Gentile CL and Pagliassotti MJ: The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19: 567-576, 2008.
3. Kaila B and Raman M: Obesity: a review of pathogenesis and management strategies. Can J Gastroenterol 22: 61-68, 2008.
4. Angulo P: Obesity and nonalcoholic fatty liver disease. Nutr Rev 65: S57-S63, 2007.
5. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G and Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 4: 72-81, 2008.
6. Parekh S and Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132: 2191-2207, 2007.
7. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV and O'Connor JE: A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165: 106-116, 2007.
8. Ricchi M, Odoardi MR, Carulli L, et al: Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24: 830-840, 2009.
9. Stapleton D, Mitchelhill KI, Gao G, et al: Mammalian AMP-activated protein kinase subfamily. J Biol Chem 271: 611-614, 1996.
10. Misra P: AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 12: 91-100, 2008.
11. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M and Andreelli F: Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33: 395-402, 2007.
12. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW and Ruderman NB: Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585, 2004.
13. Park JC, Hur JM, Park JG, Kim SC, Park JR, Choi SH and Choi JW: Effects of methanol extract of Cirsium japonicum var. ussuriense and its principle, hispidulin-7-O-neohesperidoside on hepatic alcohol-metabolizing enzymes and lipid peroxidation in ethanol-treated rats. Phytother Res 18: 19-24, 2004.
14. Clark JM, Brancati FL and Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 122: 1649-1657, 2002.
15. Ruhl CE and Everhart JE: Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 8: 501-519, 2004.
16. Ha SK, Kim J and Chae C: Role of AMP-activated protein kinase and adiponectin during development of hepatic steatosis in high-fat diet-induced obesity in rats. J Comp Pathol 145: 88-94, 2011.
17. Federico A, Niosi M, Vecchio Blanco CD and Loguercio C: Emerging drugs for nonalcoholic fatty liver disease. Expert Opin Emerg Drugs 13: 145-158, 2008.
18. Viollet B, Foretz M, Guigas B, et al: Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574: 41-53, 2006.
19. Lee WJ, Kim M, Park HS, et al: AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun 340: 291-295, 2006.
20. Lagouge M, Argmann C, Gerhart-Hines Z, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006.
21. Wang ZQ, Zhang XH, Yu Y, et al: Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. Metabolism 62: 1239-1249, 2013.
22. Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol 85: 1330-1340, 2013.